clinical trial · NCT05060822
Phase ll Study of HEC585 in Patients With IPF
Sunshine Lake Pharma Co., Ltd.·phase2·active not recruiting·n = 270
Idiopathic Pulmonary FibrosisHEC585PirfenidonePlacebo
brief summary
A Phase ll Study to evaluate the efficacy and safety of various doses of HEC585 Tablets in patients with idiopathic pulmonary fibrosis
started
Jun 30, 2021
primary completion
Jul 16, 2025
completion
Dec 11, 2026
last updated
Apr 21, 2026
official title
A Phase II, Multi-center, Randomized, Placebo-controlled (Double-blind Design), Active Comparator-controlled (Open-label Design), Parallel-group, Dose-finding Study, to Evaluate the Efficacy and Safety of HEC585 Tablets in Patients With IPF
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol